Additionally, dupilumab, an IL4R-blocking antibody approved for the treatment of atopic dermatitis, asthma, and chronic sinusitis with nasal polyposis [67,68], showed efficacy in reducing LUADBM organoid growth. Here, IL4R is linked to chronic rhinosinusitis.